Hosted on MSN6mon
Synthetic THC may decrease agitation in Alzheimer's patients
"It is the agitation, not the memory loss, that often drives individuals with dementia ... patient population currently on the market," Forester said. A pilot study had suggested that cannabinoid ...
Clinical Trials Arena on MSN3d
IGC Pharma posts promising interim data for Alzheimer’s therapy
The results suggest that IGC-AD1 may decrease the frequency and severity of sleep disturbances and night time behaviours.
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences
POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today ...